Erectile Dysfunction - Pipeline Review, H1 2017

Published: Feb, 2017 | Pages: 103 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Erectile Dysfunction - Pipeline Review, H1 2017, provides an overview of the Erectile Dysfunction (Male Health) pipeline landscape.

Erectile dysfunction, or ED, is the inability of a man to have an erection hard enough to have sexual intercourse. It can also be known as impotence. The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use and medications, including antidepressants, antihistamines and medications to treat high blood pressure, pain or prostate cancer.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Erectile Dysfunction - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Erectile Dysfunction (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Erectile Dysfunction (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 2, 5, 4, 2, 2, 11, 2 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Erectile Dysfunction (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Erectile Dysfunction (Male Health).
- The pipeline guide reviews pipeline therapeutics for Erectile Dysfunction (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Erectile Dysfunction (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Erectile Dysfunction (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Erectile Dysfunction (Male Health)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Erectile Dysfunction (Male Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Erectile Dysfunction (Male Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Erectile Dysfunction - Overview
Erectile Dysfunction - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Erectile Dysfunction - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Erectile Dysfunction - Companies Involved in Therapeutics Development
Apricus Biosciences Inc
Astellas Pharma Inc
Biolab Farmaceutica Ltda
Biopharm GmbH
Can-Fite BioPharma Ltd
Fabre-Kramer Pharmaceuticals Inc
Futura Medical Plc
Hanmi Pharmaceuticals Co Ltd
Humanetics Corp
IntelGenx Corp
Ion Channel Innovations LLC
iX Biopharma Ltd
Mezzion Pharma Co Ltd
Mitsubishi Tanabe Pharma Corp
Monosol Rx LLC
NAL Pharmaceuticals Ltd
Palatin Technologies Inc
Pharmicell Co Ltd
Suda Ltd
XuanZhu Pharma Co Ltd
Yungjin Pharm Co Ltd
Erectile Dysfunction - Drug Profiles
(tadalafil + tamsulosin hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alprostadil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avanafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIO-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BL-214 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellgram-ED - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fadanafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FKK-01PD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HCP-1302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IPED-2015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MED-2002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MED-2005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mirabegron ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Male Health - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pVAX-hSlo - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sildenafil citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sildenafil citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sildenafil citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PDE5 for Erectile Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUD-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T-6932 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tadalafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tadalafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tadalafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TF-0092 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPN-729 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TR-399 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
udenafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VLFIA-330 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YBH-1603 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Erectile Dysfunction - Dormant Projects
Erectile Dysfunction - Discontinued Products
Erectile Dysfunction - Product Development Milestones
Featured News & Press Releases
Feb 07, 2017: MonoSol Rx Receives FDA Acceptance of New Drug Application for Tadalafil PharmFilm
Jan 24, 2017: Humanetics Awarded Patent to Mitigate Erectile Dysfunction Associated with Prostate Cancer Radiotherapy
Dec 14, 2016: CFDA Granted Approval forPhase I/II/III Clinical Trials of Sihuan Pharmaceutical's Internally Developed Innovative Patented New Drug - Fadanafil
Nov 28, 2016: MonoSol Rx Submits New Drug Application for Tadalafil PharmFilm
Nov 09, 2016: Can-Fite Receives Notice of Allowance From U.S. Patent and Trademark Office for Erectile Dysfunction Drug
Sep 13, 2016: iX Biopharma Announces Positive Results from Pivotal Study of Erectile Dysfunction Drug
Jul 27, 2016: VIVUS Files Lawsuit Against Hetero for Infringement of Stendra Patents
May 02, 2016: Can-Fite to Present Data on CF602 in the Treatment of Erectile Dysfunction at American Urology Association Annual Meeting
Apr 11, 2016: Can-Fite Announces New Pre-Clinical Data for CF602 Demonstrating Statistically Significant Full Recovery from Erectile Dysfunction After a Single Dose
Mar 28, 2016: MonoSol Rx Successfully Completes Pre-IND Meeting with the FDA for PharmFilm Tadalafil
Nov 25, 2015: iX Biopharma Announces Success Of Pilot Bioavailability Study For Pheonix
Jan 29, 2015: VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA Now First and Only Oral Erectile Dysfunction Treatment Approved in Europe to Be Taken Approximately 15 Minutes Before Sexual Activity
Jan 27, 2015: Can-Fite's CF602 Demonstrates Efficacy in Treatment of Sexual Dysfunction in Preclinical Studies
Dec 09, 2014: Can-Fite to Initiate the Development Program of its Next Generation Drug CF602
Nov 20, 2014: Auxilium Pharmaceuticals Presents STENDRA Data At SMSNA Scientific Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Erectile Dysfunction, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Erectile Dysfunction - Pipeline by Apricus Biosciences Inc, H1 2017
Erectile Dysfunction - Pipeline by Astellas Pharma Inc, H1 2017
Erectile Dysfunction - Pipeline by Biolab Farmaceutica Ltda, H1 2017
Erectile Dysfunction - Pipeline by Biopharm GmbH, H1 2017
Erectile Dysfunction - Pipeline by Can-Fite BioPharma Ltd, H1 2017
Erectile Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H1 2017
Erectile Dysfunction - Pipeline by Futura Medical Plc, H1 2017
Erectile Dysfunction - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
Erectile Dysfunction - Pipeline by Humanetics Corp, H1 2017
Erectile Dysfunction - Pipeline by IntelGenx Corp, H1 2017
Erectile Dysfunction - Pipeline by Ion Channel Innovations LLC, H1 2017
Erectile Dysfunction - Pipeline by iX Biopharma Ltd, H1 2017
Erectile Dysfunction - Pipeline by Mezzion Pharma Co Ltd, H1 2017
Erectile Dysfunction - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017
Erectile Dysfunction - Pipeline by Monosol Rx LLC, H1 2017
Erectile Dysfunction - Pipeline by NAL Pharmaceuticals Ltd, H1 2017
Erectile Dysfunction - Pipeline by Palatin Technologies Inc, H1 2017
Erectile Dysfunction - Pipeline by Pharmicell Co Ltd, H1 2017
Erectile Dysfunction - Pipeline by Suda Ltd, H1 2017
Erectile Dysfunction - Pipeline by XuanZhu Pharma Co Ltd, H1 2017
Erectile Dysfunction - Pipeline by Yungjin Pharm Co Ltd, H1 2017
Erectile Dysfunction - Dormant Projects, H1 2017
Erectile Dysfunction - Dormant Projects, H1 2017 (Contd..1), H1 2017
Erectile Dysfunction - Discontinued Products, H1 2017